Trial Profile

ZYESAMI (Aviptadil) for the Treatment of Critical COVID-19 With Respiratory Failure

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 26 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aviptadil (Primary) ; Anticoagulants; Antivirals; Convalescent anti-SARS-CoV-2 plasma; Remdesivir; Steroids
Indications SARS-CoV-2 acute respiratory disease
Focus Proof of concept; Registrational; Therapeutic Use
Acronyms COVID-AIV
Sponsors NeuroRX

Most Recent Events

26 Jul 2023 Last checked against Clinicaltrials.gov record.
24 May 2023 Results (n=81) evaluating the Radiographic Assessment of Lung Edema (RALE) score, presented at the 119th International Conference of the American Thoracic Society.
01 Nov 2022 Results published in the Critical Care Medicine.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com